40 R.G. Pertwee
Begg M, Mo F-M, Offertáler L, Bátkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G (2003)
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates
a Ca2+-dependent K+ current. J Biol Chem 278:46188–46194
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-H, Vogel Z, Bisogno T, De Petrocellis L,
Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid
glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol
353:23–31
Berdyshev EV, Schmid PC, Krebsbach RJ, Hillard CJ, Huang CS, Chen N, Dong Z, Schmid
HHO(2001)Cannabinoid-receptor-independentcellsignallingbyN-acylethanolamines.
Biochem J 360:67–75
BisognoT,MelckD,BobrovMY,GretskayaNM,BezuglovVV,DePetrocellisL,DiMarzo
V (2000) N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and
inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in
vivo. Biochem J 351:817–824
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic
analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic
hydrolysis of anandamide. Br J Pharmacol 134:845–852
Breivogel CS, Childers SR (2000) Cannabinoid agonist signal transduction in rat brain:
comparison of cannabinoid agonists in receptor binding, G-protein activation, and
adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328–336
Breivogel CS, Sim LJ, Childers SR (1997) Regional differences in cannabinoid receptor/G-
protein coupling in rat brain. J Pharmacol Exp Ther 282:1632–1642
Breivogel CS, Selley DE, Childers SR (1998) Cannabinoid receptor agonist efficacy for stimu-
lating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced
decreases in GDP affinity. J Biol Chem 273:16865–16873
Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled
cannabinoid receptor in mouse brain. Mol Pharmacol 60:155–163
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C, Bifulco
M, Rice ASC, Di Marzo V, Baker D (2002) Arvanil-induced inhibition of spasticity and
persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1
receptor and cannabinoid CB1/CB2 receptors. Eur J Pharmacol 439:83–92
Busch-Petersen J, Hill WA, Fan PS, Khanolkar A, Xie X-Q, Tius MA, Makriyannis A
(1996) Unsaturated side chainβ-11-hydroxyhexahydrocannabinol analogs. J Med Chem
39:3790–3796
CalandraB,PortierM,KernéisA,DelpechM,CarillonC,LeFurG,FerraraP,ShireD
(1999) Dual intracellular signaling pathways mediated by the human cannabinoid CB1
receptor. Eur J Pharmacol 374:445–455
Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by
endogenous cannabinoids. Nature 394:277–281
Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty
acid amide, palmitylethanolamide. Eur J Pharmacol 419:191–198
Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM (1999) The endothelial
component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on
gap junctional communication. J Physiol 520:539–550
Cheer JF, Cadogan A-K, Marsden CA, Fone KCF, Kendall DA (1999) Modification of 5-
HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid
receptors. Neuropharmacology 38:533–541
Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type
calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033–7040
ChinC,Lucas-LenardJ,AbadjiV,KendallDA(1998)Ligandbindingandmodulationofcyclic
AMP levels depend on the chemical nature of residue 192 of the human cannabinoid
receptor 1. J Neurochem 70:366–373
Christopoulos A, Wilson K (2001) Interaction of anandamide with the M1 and M4 mus-
carinic acetylcholine receptors. Brain Res 915:70–78